Halting Oxford's Covid-19 vaccine trial is not a setback; it shows prudence

Melbourne-based biotechnology company CSL has committed to producing and supplying more than 30 million doses of the vaccine to Australians if it's found to be safe and effective

Only days after the federal government announced a A$1.7 billion vaccine deal to roll out Covid-19 vaccines to Australians in 2021, one of the two candidates has halted its phase 3 trials after a participant became ill.

The AZD1222 vaccine, considered one of the frontrunners in the global race for a Covid-19 vaccine, was developed by the University of Oxford and has been undergoing testing with British-Swedish pharmaceutical company AstraZeneca.

Melbourne-based biotechnology company CSL has committed to producing and supplying more than 30 million doses of the vaccine to Australians if it’s found to be safe and